Explore the Agenda
Workshop A
9:00 am Debating Active & Passive Targeting Strategies to Identify the Best Approach for Achieving Scalable, Specific, & Selective Nanoparticles
As lipid-based nanoparticles advance beyond hepatic applications, developers must evaluate whether passive or active targeting strategies best balance delivery efficiency with manufacturability and regulatory feasibility. This interactive workshop will explore the scientific, technical, and regulatory trade-offs shaping the future of extrahepatic LNP delivery.
This workshop will gather experts to discuss:
- Comparing active and passive targeting strategies, from antibody-based approaches to passive tissue tropism driven by lipid composition and emerging 5th-component designs
- Assessing efficacy and manufacturability by delving into potency, endosomal escape, scalability, CMC complexity, and ligand stability during manufacturing for active versus passive LNPs
- Delving into toxicology and pharmacology of targeting moieties, potential biological interference, and practical considerations for regulatory approval of targeted LNP system
12:00 pm Lunch Break & Networking
Workshop B
1:00 pm Designing Robust Analytics & Scalable Processes for Targeted LNPs to Achieve High Quality, Consistent Manufacturing for Clinical Readiness
Unlike traditional LNPs, targeted LNPs introduce additional layers of analytical, process, and CMC complexity due to surface-bound ligands and multi-step modifications. This workshop will examine how to align analytical development with process development and scale-up strategies to manage this complexity, ensure high product quality, and enable reliable manufacturing.
This workshop will gather experts to discuss:
- Unlocking advanced analytics for tLNPs to quantify conjugated binders, assess particle heterogeneity, and confirming ligand integrity following large-scale manufacturing
- De-risking batch-to-batch variability and maintaining CQA consistency by designing conjugation chemistry and manufacturing processes achieving uniform ligand attachment
- Navigating scale-up of tLNPs by addressing added downstream, analytical, and stability of targeting challenges not seen with traditional LNPs